Breast and reproductive cancers, such as cervical, ovarian, and endometrial cancers, are leading causes of mortality among women worldwide. While treatment advances have improved outcomes, early detection through effective screening remains the most impactful strategy to reduce mortality. However, access to and uptake of screening programs remain uneven across populations, influenced by medical, cultural, social, and economic factors. The success of screening strategies today relies not only on medical innovation but also on the coordinated actions of diverse stakeholders. Healthcare professionals, technology providers, public institutions, NGOs, and even celebrities and digital influencers, all have a role to play in increasing awareness, access, and adherence to screening protocols. In this article, Alcimed explores how these actors contribute, individually and collectively, to reshaping the landscape of cancer prevention.
Healthcare Professionals are usually the frontline stakeholders of cancer prevention. Their recommendations strongly influence patients’ decisions to undergo screening, particularly in the context of personalized risk factors. General practitioners, gynecologists, oncologists, and nurses not only initiate screening conversations but also enable access to diagnostic and specialist services.
Today, we see expanded roles for health professionals through risk-based approaches. For example, the use of familial history and BRCA testing in primary care has enabled earlier identification of at-risk patients. Studies have shown that when healthcare providers are trained in shared decision-making, screening participation increases, particularly among women hesitant due to cultural or psychological concerns.
Additionally, integration of new tools, such as AI-assisted mammography interpretation or digital colposcopy for cervical exams, requires training and trust from clinicians. In this sense, collaboration between medical professionals and technology developers is essential not only for implementation but also for gaining patient acceptance.
Technological innovation is rapidly transforming cancer screening. Companies developing diagnostic solutions, health IT platforms, and digital engagement tools are reshaping how women engage with their health.
AI-powered screening tools, such as Google Health’s mammography analysis model and iCAD’s ProFound AI®, are improving the accuracy of breast cancer detection by reducing false positives and enabling faster diagnosis. Such solutions also help alleviate the pressure on overburdened radiology departments.
In cervical cancer, AI-assisted digital colposcopy (e.g., MobileODT’s EVA system) has been deployed in Low and Middle Income Countries to aid community health workers in making accurate assessments without requiring a pathologist on-site.
The adoption of self-sampling HPV kits is another game-changer. Studies demonstrate that self-sampling increases participation by up to 15% among non-responders to traditional Pap smear invitations. Companies like Hologic and Roche Diagnostics are actively developing and marketing at-home kits, making cervical cancer screening more accessible, particularly for underserved women.
Public institutions design, finance, and regulate national screening programs. Their policies determine how equitably and effectively these programs operate.
The UK’s NHS Breast Screening Programme and France’s organized campaigns exemplify structured, population-wide approaches. However, success depends not just on availability but on design and engagement. France, for instance, has struggled to surpass 50% participation in breast screening despite national coverage. As a response, the Institut National du Cancer (INCa) has piloted behavioural economics interventions, like personalized invitations and reminder texts, to boost uptake.
In the Netherlands and Finland, use of national cancer registries enables stratified invitations based on individual risk profiles, increasing both effectiveness and efficiency. Meanwhile, countries like Australia are leading the way with integrated HPV vaccination and screening programs, aiming to eliminate cervical cancer as a public health problem by 2035.
Governments are also investing in risk-adapted screening. In the USA, the WISDOM study explores personalized breast cancer screening based on genetic, lifestyle, and medical data, moving away from a one-size-fits-all approach.
NGOs often fill structural gaps in healthcare systems by supporting education, reducing stigma, and facilitating access.
Campaigns such as Breast Cancer Awareness Month, the Pink Ribbon movement, and WHO’s Cervical Cancer Elimination Initiative have succeeded in normalizing conversations around reproductive cancers.
These groups also combat misinformation and build culturally appropriate narratives. For example, Ovarian Cancer Action in the UK launched a campaign using real stories to help women recognize the vague symptoms of ovarian cancer, which is often diagnosed late (see our logbook article on this topic).
Additionally, NGOs often partner with corporate actors to expand their reach, e.g., Unilever and NGOs in India co-developing hygiene and screening campaigns that align with menstrual health education.
The power of public figures in promoting screening is measurable and profound. When actress Angelina Jolie disclosed her preventive double mastectomy due to BRCA1 mutation, referrals for genetic counselling suddenly increased by 90% within six months, a phenomenon called the “Angelina Jolie Effect”.
More recently, influencer-led campaigns have demonstrated measurable effects behaviour. Research from WEGO Health shows that 85% of patients would trust a pharmaceutical product if endorsed by a health influencer, and 93% would consult their healthcare professional based on influencer content. This makes influencers important allies in reaching younger, tech-savvy population who may not respond to traditional health messaging.
Additionally, campaigns like “Know Your Lemons” creatively use visual storytelling on social media to explain breast cancer symptoms in a relatable way. These campaigns have proven especially impactful in reducing stigma in conservative or low-literacy populations.
Learn more about how our team can support you in your projects related to women’s health >
While many initiatives exist, challenges remain. Screening disparities persist across socioeconomic, racial, and geographic lines. To close these gaps, future strategies must include:
Maximizing the reach and impact of breast and reproductive cancer screening requires a multi-stakeholder approach. Healthcare providers, governments, NGOs, technology firms, and public figures all have distinct but complementary roles. Their combined actions, from technological development to policy design and cultural influence, are vital to transforming screening from a medical recommendation into a societal norm. At Alcimed, we are here to help you explore synergies! Do not hesitate to contact our team.
About the author,
Diane, Project Manager in Alcimed’s Life Sciences team in Germany
Healthcare
What are the current infertility treatments? To date, there are 3 main infertility treatments available: Medications They are used to control hormones and stimulate ovulation. They can be used ...
Healthcare
Facilitating the diagnosis of endometriosis for better patient care is one of the major challenges in improving the health and quality of life of women affected. What are the solutions?
Healthcare
Intraoperative detection of cancer cells is a new and innovative form of interventional oncology. It has been applied in diagnosis, treatment or symptom easement and brings along minimal invasive ...